News
Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA 1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback